Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRISTOL MYERS SQUIBB COBMY · Entity 1662 | Director | June 15, 2026 | June 16, 2026 |
| HYPERION DEFI, INC.EYEN · Entity 7220 | Director | June 16, 2022 | June 21, 2022 |
| Outlook Therapeutics, Inc.OTLK · Entity 608 | Director | October 01, 2025 | October 04, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRISTOL MYERS SQUIBB CO
Report date June 15, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.10 par valueSEC Table I · non-derivative | Direct | 34,079 |
Reported balance
After 2026-06-15 transaction · row 1
1 source rowRow 1 · 2026-06-15 · Exercise / conversion · Acquired 20,460 · Balance 34,079 |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $53.76 · Expires 2026-06-15 | Direct | 0 |
Reported balance
After 2026-06-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-15 · Exercise / conversion · Disposed 20,460 · Balance 0 F1: The reporting person made a cash exercise of an option and is currently holding the underlying shares. F2: All of the shares are currently exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person made a cash exercise of an option and is currently holding the underlying shares.
F2: All of the shares are currently exercisable.
HYPERION DEFI, INC.
Report date June 16, 2022 · Filed June 21, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $.0001SEC Table I · non-derivative | Direct | 30,408 |
Reported balance
After 2022-06-16 transaction · row 1
1 source rowRow 1 · 2022-06-16 · Grant · Acquired 22,222 · Balance 30,408 F1: Represents restricted stock units that fully vest on the earlier of June 16, 2023 or the date of the Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.80 · Expires 2032-06-16 | Direct | 30,769 |
Reported balance
After 2022-06-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-06-16 · Grant · Acquired 30,769 · Balance 30,769 F2: The option becomes exercisable on the earlier of June 16, 2023 or the date of the Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units that fully vest on the earlier of June 16, 2023 or the date of the Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control.
F2: The option becomes exercisable on the earlier of June 16, 2023 or the date of the Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control.
Outlook Therapeutics, Inc.
Report date October 01, 2025 · Filed October 04, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.04 · Expires 2035-10-01 | Direct | 286,734 |
Reported balance
After 2025-10-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-10-01 · Grant · Acquired 286,734 · Balance 286,734 F1: This option grant is an annual stock option grant under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the "2024 Plan") and shall fully vest on October 1, 2026, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.06 · Expires 2035-10-03 | Direct | 58,648 |
Reported balance
After 2025-10-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-10-03 · Grant · Acquired 58,648 · Balance 58,648 F2: The options were granted under the 2024 Plan in lieu of $55,000 cash fees payable under the Issuer's Non-Employee Director Compensation Policy and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2026, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control. |
Filing footnotes · ownership attribution and instrument terms
F1: This option grant is an annual stock option grant under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the "2024 Plan") and shall fully vest on October 1, 2026, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control.
F2: The options were granted under the 2024 Plan in lieu of $55,000 cash fees payable under the Issuer's Non-Employee Director Compensation Policy and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2026, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CELGENE CORP /DE/
Report date November 20, 2019 · Filed November 22, 2019
Section 16 reporting ended · disclosed 2019-11-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 1
1 source rowRow 1 · 2019-11-20 · Disposition to issuer · Disposed 2,409 · Balance 0 F1: Reflects disposition in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one contingent value right ("CVR") issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $117.53 · Expires 2025-10-15 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-11-20 · Disposition to issuer · Disposed 10,000 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $99.98 · Expires 2026-06-15 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-11-20 · Disposition to issuer · Disposed 11,000 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $121.04 · Expires 2027-06-14 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-11-20 · Disposition to issuer · Disposed 10,500 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $77.38 · Expires 2028-06-13 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-11-20 · Disposition to issuer · Disposed 13,266 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-11-20 · Disposition to issuer · Disposed 300 · Balance 0 F4: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F5: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-11-20 · Disposition to issuer · Disposed 970 · Balance 0 F4: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F5: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-11-20 · Disposition to issuer · Disposed 4,756 · Balance 0 F4: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F5: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects disposition in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one contingent value right ("CVR") issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company.
F2: This option was fully exercisable.
F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.
F4: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock.
F5: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 03, 2020 Filed Jun 5, 2020 20:39 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 2,949 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-20-000176 · wf-form4_159138957133577.xml · nonDerivative · entry 1 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,358 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On June 3, 2019, the reporting person was granted 8,847 restricted stock units, vesting in three equal installments beginning on June 3, 2020. F2 · price: Each restricted stock unit converts into one share of common stock upon vesting. Read SEC document |
| March 31, 2020 Filed Apr 2, 2020 20:53 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 515.788 | $55.74 | $28,750.02 |
DisclosureSEC source: 0000014272-20-000146 · wf-form4_158586077133560.xml · derivative · entry 1 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,369.029 Underlying: Common Stock, $0.10 par value · 515.788 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| February 01, 2020 Filed Feb 4, 2020 23:06 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 3,018.268 | $62.95 | $189,999.97 |
DisclosureSEC source: 0000014272-20-000063 · wf-form4_158085760016384.xml · derivative · entry 1 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,853.241 Underlying: Common Stock, $0.10 par value · 3,018.268 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 23:49 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 177.802 | $64.19 | $11,413.11 |
DisclosureSEC source: 0000014272-20-000019 · wf-form4_157809537433269.xml · derivative · entry 1 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 833.715 Underlying: Common Stock, $0.10 par value · 177.802 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:30 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerRestricted Stock Unit · Derivative | 4,756 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-001370 · form4-11222019_071142.xml · derivative · entry 8 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,756 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F5 · price: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. F5 · derivative.exercise_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. F5 · derivative.expiration_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:30 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerRestricted Stock Unit · Derivative | 970 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-001370 · form4-11222019_071142.xml · derivative · entry 7 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 970 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F5 · price: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. F5 · derivative.exercise_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. F5 · derivative.expiration_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:30 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerRestricted Stock Unit · Derivative | 300 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-001370 · form4-11222019_071142.xml · derivative · entry 6 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 300 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F5 · price: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. F5 · derivative.exercise_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. F5 · derivative.expiration_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:30 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 13,266 | $0.00 Strike: $77.38 | $0.00 |
DisclosureSEC source: 0001415889-19-001370 · form4-11222019_071142.xml · derivative · entry 5 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,266 shares Expires 2028-06-13 F3 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: This option was fully exercisable. F3 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:30 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 10,500 | $0.00 Strike: $121.04 | $0.00 |
DisclosureSEC source: 0001415889-19-001370 · form4-11222019_071142.xml · derivative · entry 4 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,500 shares Expires 2027-06-14 F3 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: This option was fully exercisable. F3 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:30 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $99.98 | $0.00 |
DisclosureSEC source: 0001415889-19-001370 · form4-11222019_071142.xml · derivative · entry 3 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,000 shares Expires 2026-06-15 F3 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: This option was fully exercisable. F3 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:30 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $117.53 | $0.00 |
DisclosureSEC source: 0001415889-19-001370 · form4-11222019_071142.xml · derivative · entry 2 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2025-10-15 F3 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: This option was fully exercisable. F3 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:30 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerCommon Stock | 2,409 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-001370 · form4-11222019_071142.xml · nonDerivative · entry 1 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Reflects disposition in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one contingent value right ("CVR") issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 22:00 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 655.913 | $56.41 | $37,000.05 |
DisclosureSEC source: 0000014272-19-000205 · wf-form4_157446000139234.xml · derivative · entry 1 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 655.913 Underlying: Common Stock, $0.10 par value · 655.913 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · shares: Represents pro rata portion of the 2019 annual Deferred Share Units awards granted to the Company's directors. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. Read SEC document |
| November 20, 2019 Filed Nov 27, 2019 22:41 UTC Amendment | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantRestricted Stock Units · Derivative | 8,847 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-19-000225 · wf-form4a_157489447562015.xml · derivative · entry 8 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,847 Underlying: Common Stock, $0.10 par value · 8,847 shares Expires 2022-06-03 F5 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F8 · derivative.exercise_price: The restricted stock unit vests in three equal annual installments beginning on June 3, 2020. F5 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting. F8 · derivative.exercise_date: The restricted stock unit vests in three equal annual installments beginning on June 3, 2020. Read SEC document |
| November 20, 2019 Filed Nov 27, 2019 22:41 UTC Amendment | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantRestricted Stock Units · Derivative | 1,805 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-19-000225 · wf-form4a_157489447562015.xml · derivative · entry 7 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,805 Underlying: Common Stock, $0.10 par value · 1,805 shares Expires 2021-06-13 F5 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F7 · derivative.exercise_price: The restricted stock unit vests in three equal annual installments beginning on June 13, 2019. F5 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting. F7 · derivative.exercise_date: The restricted stock unit vests in three equal annual installments beginning on June 13, 2019. Read SEC document |
| November 20, 2019 Filed Nov 27, 2019 22:41 UTC Amendment | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantRestricted Stock Units · Derivative | 558 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-19-000225 · wf-form4a_157489447562015.xml · derivative · entry 6 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 558 Underlying: Common Stock, $0.10 par value · 558 shares Expires 2020-06-14 F5 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F6 · derivative.exercise_price: The restricted stock unit vests in three equal annual installments beginning on June 14, 2018. F5 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting. F6 · derivative.exercise_date: The restricted stock unit vests in three equal annual installments beginning on June 14, 2018. Read SEC document |
| November 20, 2019 Filed Nov 27, 2019 22:41 UTC Amendment | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantOption (right to buy) · Derivative | 24,674 | $0.00 Strike: $41.61 | $0.00 |
DisclosureSEC source: 0000014272-19-000225 · wf-form4a_157489447562015.xml · derivative · entry 5 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,674 Underlying: Common Stock, $0.10 par value · 24,674 shares Expires 2028-06-13 F4 · derivative.exercise_date: All of the shares are currently exercisable. Pursuant to the Merger, the stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 27, 2019 22:41 UTC Amendment | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantOption (right to buy) · Derivative | 19,635 | $0.00 Strike: $64.73 | $0.00 |
DisclosureSEC source: 0000014272-19-000225 · wf-form4a_157489447562015.xml · derivative · entry 4 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,635 Underlying: Common Stock, $0.10 par value · 19,635 shares Expires 2027-06-14 F4 · derivative.exercise_date: All of the shares are currently exercisable. Pursuant to the Merger, the stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 27, 2019 22:41 UTC Amendment | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantOption (right to buy) · Derivative | 20,460 | $0.00 Strike: $53.76 | $0.00 |
DisclosureSEC source: 0000014272-19-000225 · wf-form4a_157489447562015.xml · derivative · entry 3 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,460 Underlying: Common Stock, $0.10 par value · 20,460 shares Expires 2026-06-15 F4 · derivative.exercise_date: All of the shares are currently exercisable. Pursuant to the Merger, the stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 27, 2019 22:41 UTC Amendment | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantOption (right to buy) · Derivative | 18,700 | $0.00 Strike: $62.86 | $0.00 |
DisclosureSEC source: 0000014272-19-000225 · wf-form4a_157489447562015.xml · derivative · entry 2 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,700 Underlying: Common Stock, $0.10 par value · 18,700 shares Expires 2025-10-15 F4 · derivative.exercise_date: All of the shares are currently exercisable. Pursuant to the Merger, the stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 27, 2019 22:41 UTC Amendment | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantCommon Stock, $0.10 par value | 2,409 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-19-000225 · wf-form4a_157489447562015.xml · nonDerivative · entry 1 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,409 F1 · shares: Total includes 200 shares held jointly with spouse in a brokerage account. F2 · shares: On November 20, 2019 ("Closing Date"), Bristol-Myers Squibb Company ("BMS") completed the previously announced acquisition of Celgene Corporation ("Celgene") contemplated pursuant to the terms and conditions of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 2, 2019, by and among BMS, Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), and Celgene. Under the Merger Agreement, Merger Sub merged with and into Celgene with Celgene surviving as a direct wholly owned subsidiary of BMS (the "Merger"). Due to an administrative delay in calculations surrounding the total Merger Consideration (defined below) received by the Reporting Person, this Form 4 is being amended to report the correct number of securities beneficially owned by the Reporting Person. F3 · shares: Pursuant to the Merger, each outstanding share of Celgene common stock, par value $0.01 per share, was converted into the right to receive (x) $50 in cash, without interest, (y) one share of BMS common stock, par value $0.10 per share and (z) one tradeable contingent value right ( "CVR") per share or, with respect to equity awards (in some cases), per share underlying each such equity award ("Merger Consideration"). Each CVR will represent the right to receive $9.00 in cash upon Federal Drug Administration ("FDA") approval of a specified set of milestones, as set forth in the Contingent Value Rights Agreement, dated as of November 20, 2019, between BMS and Equiniti Trust Company, as trustee. Read SEC document |
| June 15, 2019 Filed Jun 17, 2019 16:00 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionRestricted Stock Unit · Derivative | 375 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-000725 · form4-06172019_040602.xml · derivative · entry 6 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The remaining one-third of the restricted stock units granted to the reporting person on June 15, 2016 vested and settled for shares of the Company's common stock. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F6 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the Company's 2008 Stock Incentive Plan). F3 · derivative.exercise_date: The remaining one-third of the restricted stock units granted to the reporting person on June 15, 2016 vested and settled for shares of the Company's common stock. F3 · derivative.expiration_date: The remaining one-third of the restricted stock units granted to the reporting person on June 15, 2016 vested and settled for shares of the Company's common stock. Read SEC document |
| June 15, 2019 Filed Jun 17, 2019 16:00 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 375 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-000725 · form4-06172019_040602.xml · nonDerivative · entry 3 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,409 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: The remaining one-third of the restricted stock units granted to the reporting person on June 15, 2016 vested and settled for shares of the Company's common stock. Read SEC document |
| June 14, 2019 Filed Jun 17, 2019 16:00 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionRestricted Stock Unit · Derivative | 300 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-000725 · form4-06172019_040602.xml · derivative · entry 5 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300 Underlying: Common Stock · 300 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: One-third of the restricted stock units granted to the reporting person on June 14, 2017 vested and settled for shares of the Company's common stock. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F7 · derivative.exercise_price: The remainder of the restricted stock units will vest as follows: 300 shares on June 14, 2020. Vested shares will be delivered to the reporting person promptly after the vesting date. F6 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the Company's 2008 Stock Incentive Plan). F2 · derivative.exercise_date: One-third of the restricted stock units granted to the reporting person on June 14, 2017 vested and settled for shares of the Company's common stock. F2 · derivative.expiration_date: One-third of the restricted stock units granted to the reporting person on June 14, 2017 vested and settled for shares of the Company's common stock. Read SEC document |
| June 14, 2019 Filed Jun 17, 2019 16:00 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 300 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-000725 · form4-06172019_040602.xml · nonDerivative · entry 2 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,034 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: One-third of the restricted stock units granted to the reporting person on June 14, 2017 vested and settled for shares of the Company's common stock. Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 16:00 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionRestricted Stock Unit · Derivative | 484 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-000725 · form4-06172019_040602.xml · derivative · entry 4 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 970 Underlying: Common Stock · 484 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: One-third of the restricted stock units granted to the reporting person on June 13, 2018 vested and settled for shares of the Company's common stock. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F5 · derivative.exercise_price: The remainder of the restricted stock units will vest in two annual installments as follows: 485 shares on June 13, 2020 and 485 shares on June 13, 2021. Vested shares will be delivered to the reporting person promptly after the vesting date. F6 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the Company's 2008 Stock Incentive Plan). F1 · derivative.exercise_date: One-third of the restricted stock units granted to the reporting person on June 13, 2018 vested and settled for shares of the Company's common stock. F1 · derivative.expiration_date: One-third of the restricted stock units granted to the reporting person on June 13, 2018 vested and settled for shares of the Company's common stock. Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 16:00 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 484 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-000725 · form4-06172019_040602.xml · nonDerivative · entry 1 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,734 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: One-third of the restricted stock units granted to the reporting person on June 13, 2018 vested and settled for shares of the Company's common stock. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 16:05 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantRestricted Stock Unit · Derivative | 4,756 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-000661 · form4-06052019_040607.xml · derivative · entry 1 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,756 Underlying: Common Stock · 4,756 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F3 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan. F2 · derivative.exercise_date: The restricted stock units will vest in three annual installments as follows: 1,585 shares on June 3, 2020; 1,585 shares on June 3, 2021; and 1,586 shares on June 3, 2022. Vested shares will be delivered to the reporting person promptly after the vesting date. F2 · derivative.expiration_date: The restricted stock units will vest in three annual installments as follows: 1,585 shares on June 3, 2020; 1,585 shares on June 3, 2021; and 1,586 shares on June 3, 2022. Vested shares will be delivered to the reporting person promptly after the vesting date. Read SEC document |
| June 15, 2018 Filed Jun 15, 2018 16:57 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionRestricted Stock Unit · Derivative | 375 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-18-000945 · form4-06152018_010643.xml · derivative · entry 6 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375 Underlying: Common Stock · 375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: One-third of the restricted stock units granted to the reporting person June 15, 2016 vested and settled for shares of the Company's common stock. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F9 · derivative.exercise_price: The remainder of the restricted stock units will vest on June 15, 2019. Vested shares will be delivered to the reporting person promptly after the vesting date. F5 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan. F2 · derivative.exercise_date: One-third of the restricted stock units granted to the reporting person June 15, 2016 vested and settled for shares of the Company's common stock. F2 · derivative.expiration_date: One-third of the restricted stock units granted to the reporting person June 15, 2016 vested and settled for shares of the Company's common stock. Read SEC document |
| June 15, 2018 Filed Jun 15, 2018 16:57 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 375 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-18-000945 · form4-06152018_010643.xml · nonDerivative · entry 2 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: One-third of the restricted stock units granted to the reporting person June 15, 2016 vested and settled for shares of the Company's common stock. Read SEC document |
| June 14, 2018 Filed Jun 15, 2018 16:57 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionRestricted Stock Unit · Derivative | 300 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-18-000945 · form4-06152018_010643.xml · derivative · entry 5 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600 Underlying: Common Stock · 300 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: One-third of the restricted stock units granted to the reporting person on June 14, 2017 vested and settled for shares of the Company's common stock. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F8 · derivative.exercise_price: The remainder of the restricted stock units will vest in two annual installments as follows: 300 shares on June 14, 2019 and 300 shares on June 14, 2020. Vested shares will be delivered to the reporting person promptly after the vesting date. F5 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan. F1 · derivative.exercise_date: One-third of the restricted stock units granted to the reporting person on June 14, 2017 vested and settled for shares of the Company's common stock. F1 · derivative.expiration_date: One-third of the restricted stock units granted to the reporting person on June 14, 2017 vested and settled for shares of the Company's common stock. Read SEC document |
| June 14, 2018 Filed Jun 15, 2018 16:57 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 300 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-18-000945 · form4-06152018_010643.xml · nonDerivative · entry 1 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: One-third of the restricted stock units granted to the reporting person on June 14, 2017 vested and settled for shares of the Company's common stock. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 16:57 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantStock Option (right to buy) · Derivative | 13,266 | $0.00 Strike: $77.38 | $0.00 |
DisclosureSEC source: 0001415889-18-000945 · form4-06152018_010643.xml · derivative · entry 4 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,266 Underlying: Common Stock · 13,266 shares Expires 2028-06-13 F7 · price: The option was issued pursuant to the Company's 2017 Stock Incentive Plan. F6 · derivative.exercise_date: Option is immediately exercisable and will vest on the earlier of June 13, 2019 or the day preceding the date of the next stockholder meeting. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 16:57 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantRestricted Stock Unit · Derivative | 1,454 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-18-000945 · form4-06152018_010643.xml · derivative · entry 3 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,454 Underlying: Common Stock · 1,454 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F5 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan. F4 · derivative.exercise_date: The restricted stock units will vest in three annual installments as follows: 484 shares on June 13, 2019; 485 shares on June 13, 2020; and 485 shares on June 13, 2021. Vested shares will be delivered to the reporting person promptly after the vesting date. F4 · derivative.expiration_date: The restricted stock units will vest in three annual installments as follows: 484 shares on June 13, 2019; 485 shares on June 13, 2020; and 485 shares on June 13, 2021. Vested shares will be delivered to the reporting person promptly after the vesting date. Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 16:09 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionRestricted Stock Unit · Derivative | 375 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-040456 · doc4.xml · derivative · entry 4 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750 Underlying: Common Stock · 375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: One-third of the restricted stock units granted to the reporting person on June 15, 2016 vested and settled for shares of the Company's common stock. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F7 · derivative.exercise_price: The remainder of the restricted stock units will vest as follows: 375 shares on June 15, 2018; 375 shares on June 15, 2019. Vested shares will be delivered to the reporting person promptly after the vesting date. F6 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan. F1 · derivative.exercise_date: One-third of the restricted stock units granted to the reporting person on June 15, 2016 vested and settled for shares of the Company's common stock. F1 · derivative.expiration_date: One-third of the restricted stock units granted to the reporting person on June 15, 2016 vested and settled for shares of the Company's common stock. Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 16:09 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 375 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-040456 · doc4.xml · nonDerivative · entry 1 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 575 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: One-third of the restricted stock units granted to the reporting person on June 15, 2016 vested and settled for shares of the Company's common stock. Read SEC document |
| June 14, 2017 Filed Jun 16, 2017 16:09 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantRestricted Stock Unit · Derivative | 900 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-040456 · doc4.xml · derivative · entry 3 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 900 Underlying: Common Stock · 900 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F6 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan. F5 · derivative.exercise_date: The restricted stock units will vest in three equal annual installments commencing on June 14, 2018. Vested shares will be delivered to the reporting person promptly after the vesting date. F5 · derivative.expiration_date: The restricted stock units will vest in three equal annual installments commencing on June 14, 2018. Vested shares will be delivered to the reporting person promptly after the vesting date. Read SEC document |
| June 14, 2017 Filed Jun 16, 2017 16:09 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantStock Option (right to buy) · Derivative | 10,500 | $0.00 Strike: $121.04 | $0.00 |
DisclosureSEC source: 0001209191-17-040456 · doc4.xml · derivative · entry 2 Haller Julia A · CIK 0001656082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Common Stock · 10,500 shares Expires 2027-06-14 F3 · price: The option was issued pursuant to the Company's 2017 Stock Incentive Plan. F2 · derivative.exercise_date: Option is immediately exercisable and will vest on the earlier of June 14, 2018 or the day preceding the date of the next annual stockholder meeting. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.